Subcutaneous Epcoritamab in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma: Preliminary Phase 1/2 Results

被引：0
|
作者：
Linton, Kim M. [1 ,2 ]
Wahlin, Bjorn [3 ,4 ]
Leppa, Sirpa [5 ]
Morschhauser, Franck [6 ]
Elliott, Brian [7 ]
Liu, Tracy [7 ]
Stirner, Mariana Cota [8 ]
Abbas, Aqeel [7 ]
Falchi, Lorenzo [9 ]
机构：
[1] Christie NHS Fdn Trust, Manchester, Lancs, England
[2] Manchester Canc Res Ctr, Manchester, Lancs, England
[3] Karolinska Inst, Stockholm, Sweden
[4] Helsinki Univ Hosp, Ctr Comprehens Canc, Helsinki, Finland
[5] Univ Helsinki, Helsinki, Finland
[6] Univ Lille, CHU Lille, Lille, France
[7] Genmab, Princeton, NJ USA
[8] AbbVie, N Chicago, IL 60064 USA
[9] Mem Sloan Kettering Canc Ctr, Lymphoma Serv, New York, NY USA
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2022年 / 197卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
BSH22-PO53
引用
收藏
页码：94 / 94
页数：1
相关论文
共 50 条
  • [21] Updated interim analysis of the randomized phase 1b/3 study of tazemetostat in combination with lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma.
    Batlevi, Connie Lee
    Park, Steven I.
    Phillips, Tycel Jovelle
    Amengual, Jennifer
    Andorsky, David Jacob
    Campbell, Philip
    Mckay, Pamela
    Leonard, John Paul
    Sondhi, Manu
    Yang, Jay
    Chen, Yingxue
    O'Connor, Heather
    Slatcher, Pamela
    Morschhauser, Franck
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [22] inMIND: A phase 3 study of tafasitamab plus lenalidomide and rituximab versus placebo plus lenalidomide and rituximab for relapsed/refractory follicular or marginal zone lymphoma.
    Sehn, Laurie Helen
    Hubel, Kai
    Luminari, Stefano
    Salar, Antonio
    Wahlin, Bjorn E.
    Gopal, Ajay K.
    Bonnet, Christophe Marc
    Paneesha, Shankara
    Trneny, Marek
    Mashegu, Hafsat Umar
    Lihou, Christine Francis
    Li, Di
    Scholz, Christian W.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [23] Subcutaneous Epcoritamab in Relapsed or Refractory Large B-Cell Lymphoma: Pivotal Results from the Phase 2 EPCORE NHL-1 Trial
    Catherine, Thieblemont
    Tycel, Phillips
    Herve, Ghesquieres
    Cheah, Chan Y.
    David, Cunningham
    Do, Young R.
    Tatyana, Feldman
    Robin, Gasiorowski Robin
    Wojciech, Jurczak
    Tae, Min Kim Tae M.
    Lewis, David J.
    Mariolein, Van der Poe
    Poon, Michelle L.
    Thomas, Doerr
    Nurgul, Kilavuz
    Menghui, Chen
    Mariana, Sacchi
    Martin, Hutchings
    Pieternella, Lugtenburg
    Roost, Clausen Michael
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 : S31 - S32
  • [24] Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial
    M Wang
    N Fowler
    N Wagner-Bartak
    L Feng
    J Romaguera
    S S Neelapu
    F Hagemeister
    M Fanale
    Y Oki
    B Pro
    J Shah
    S Thomas
    A Younes
    C Hosing
    L Zhang
    K J Newberry
    M Desai
    N Cheng
    M Badillo
    M Bejarano
    Y Chen
    K H Young
    R Champlin
    L Kwak
    L Fayad
    Leukemia, 2013, 27 : 1902 - 1909
  • [25] Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial
    Wang, M.
    Fowler, N.
    Wagner-Bartak, N.
    Feng, L.
    Romaguera, J.
    Neelapu, S. S.
    Hagemeister, F.
    Fanale, M.
    Oki, Y.
    Pro, B.
    Shah, J.
    Thomas, S.
    Younes, A.
    Hosing, C.
    Zhang, L.
    Newberry, K. J.
    Desai, M.
    Cheng, N.
    Badillo, M.
    Bejarano, M.
    Chen, Y.
    Young, K. H.
    Champlin, R.
    Kwak, L.
    Fayad, L.
    LEUKEMIA, 2013, 27 (09) : 1902 - 1909
  • [26] A Phase 2, Open-Label, Multicenter Study of Tazemetostat in Combination with Rituximab for the Treatment of Relapsed or Refractory Follicular Lymphoma
    Patel, Krish
    Bailey, Neil
    Pagel, John M.
    BLOOD, 2020, 136
  • [27] R2: Preliminary Results of a Phase II Study of Lenalidomide and Rituximab in Relapsed Refractory Indolent Non-Hodgkin's Lymphoma (NHL).
    Dutia, Mrinal
    DeRoock, Ian
    Chee, Karen
    O'donnell, Robert
    Quirch, Christine
    Reed-Pease, Christine
    Tuscano, Joseph
    BLOOD, 2009, 114 (22) : 670 - 670
  • [28] R2: Preliminary Results of a Phase II Study of Lenalidomide and Rituximab in Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (NHL)
    DeRook, Ian
    Odonnell, Robert T.
    Noble, B.
    Quirch, C.
    Tuscano, Joseph
    BLOOD, 2008, 112 (11) : 1052 - 1052
  • [29] Combination of Lenalidomide and Rituximab in Elderly Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Phase 2 Trial
    Zinzani, Pier Luigi
    Pellegrini, Cinzia
    Gandolfi, Letizia
    Stefoni, Vittorio
    Quirini, Federica
    Derenzini, Enrico
    Broccoli, Alessandro
    Argnani, Lisa
    Pileri, Stefano
    Baccarani, Michele
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2011, 11 (06): : 462 - 466
  • [30] Subcutaneous Epcoritamab in Patients With Relapsed or Refractory Large B-Cell Lymphoma (EPCORE NHL-1): Pivotal Results from a Phase 2 Study
    Thieblemont, Catherine
    Phillips, Tycel
    Ghesquieres, Herve
    Cheah, Chan Y.
    Clausen, Michael Roost
    Cunningham, David
    Do, Young Rok
    Feldman, Tatyana
    Gasiorowski, Robin
    Jurczak, Wojciech
    Kim, Tae Min
    Lewis, David John
    van der Poel, Marjolein
    Poon, Michelle Limei
    Doerr, Thomas
    Kilavuz, Nurgul
    Chen, Menghui
    Sacchi, Mariana
    Elliott, Brian
    Hutchings, Martin
    Lugtenburg, Pieternella
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S379 - S379
12345